Pancreatic Cancer (Germany)
About this PSP
The PSP Pankreaskarzinom (PSP in Pancreatic Cancer based in Germany) was launched in 2017 to bring together patients, relatives, nurses and doctors to find the most important unanswered questions regarding the therapy and management of pancreatic cancer and to stimulate clinically relevant research.
The project was carried out by the Surgical University Clinic in Heidelberg, Germany in collaboration with the James Lind Alliance and is supported by the ethics committee of the Medical Faculty of the University of Heidelberg.
The PSP Top 10 was published in April 2020.
Key documents
Top 10 Priorities
- How can the best treatment for each individual patient with pancreatic cancer be identified (e.g. regarding surgery and chemotherapy)?
- Does the extent of resection (e.g. extent of lymph-node removal, extent of pancreatic resection, extent of resection of tissue on the vessels) influence survival time and quality of life?
- How are complications after pancreatic surgery best treated?
- What is the most effective treatment for metastases of pancreatic cancer?
- How can adverse effects and long-term damage from medicinal treatment be avoided?
- Does nutrition influence the survival and/or quality of life of patients with pancreatic cancer (e.g. after surgery or during chemotherapy?
- How can patients with pancreatic cancer be offered a holistic treatment package (survival time, quality of life, mobility, autonomy...)?
- What chemotherapy protocol is best for what pancreatic cancer tumour stage?
- How can the treatment goals (quality versus prolongation of life) best be explained to patients in the palliative scenario (incurable disease)?
- Which of the new treatment options for pancreatic cancer [e.g. CRISPR/Cas9 (gene scissors), KRAS, personalised peptide vaccination, hormone treatment] are effective?